Revolution Medicines




MarketCap US

US United States


Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.


Revolution Medicines was founded in 2016. It engaged in a global collaboration agreement with Genentech, a member of the Roche Group, and was granted more than $125 million in funding.

Revolution Medicines is dedicated to transforming the treatment of cancer and chronic viral diseases by targeting critical regulatory pathways.

Revolution Medicines’ vision is to realise the promise of precision medicine by discovering and developing precision oncology and curative treatments for cancers and other serious diseases.

Key Team

Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. (Pres of R&D)

Ms. Xiaolin Wang (Exec. VP of Clinical Devel.)

Dr. Martin D. Burke M.D., Ph.D. (Co-Founder & Chairman of Scientific Advisory Board)

Dr. Michael A. Fischbach Ph.D. (Academic Co-Founder & Member of Scientific Advisory Board)

Dr. Kevan M. Shokat Ph.D. (Academic Co-Founder & Member of Scientific Advisory Board)

Mr. David L. Pompliano Ph.D. (Founding Chief Scientific Officer)

Mr. Walter Reiher Ph.D. (Chief Information Officer)

Recognition and Awards
Revolution Medicines has been named the 16th fastest-growing company in 2018 according to Deloitte’s Fast 500 List and the 31st fastest-growing in the 2019 list.

Revolution Medicines
Leadership team

Dr. Mark A. Goldsmith Ph.D. (CEO, Pres & Chairman)

Mr. Jack Anders (Chief Financial Officer)

Ms. Margaret A. Horn J.D. (Chief Operating Officer)

Products/ Services
Health Care, Life Science, Medical
Number of Employees
100 - 500
Redwood City, California, United States
Company Registration
SEC CIK number: 0001628171
20M - 100M
Traded as
Social Media
Wed Feb 28 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium